Xilio Therapeutics Goodwill and Intangible Assets 2021-2025 | XLO

Xilio Therapeutics goodwill and intangible assets from 2021 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Xilio Therapeutics Goodwill and Intangible Assets 2021-2025 | XLO

Xilio Therapeutics goodwill and intangible assets from 2021 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$222.7B
Amgen (AMGN)$161.5B
Gilead Sciences (GILD)$142.5B
Vertex Pharmaceuticals (VRTX)$123.1B
Bristol Myers Squibb (BMY)$98.7B
GSK (GSK)$81B
CSL (CSLLY)$78.2B
Regeneron Pharmaceuticals (REGN)$60.4B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$34.4B
BioNTech SE (BNTX)$27.4B
Royalty Pharma (RPRX)$20.3B
Biogen (BIIB)$19.8B
Insmed (INSM)$18.3B
Illumina (ILMN)$15.8B
Genmab (GNMSF)$14B
Genmab (GMAB)$14B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.3B
Exelixis (EXEL)$12.3B
BioMarin Pharmaceutical (BMRN)$11.3B
QIAGEN (QGEN)$10.8B
Ascendis Pharma (ASND)$10.8B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Regencell Bioscience Holdings (RGC)$8.2B
Roivant Sciences (ROIV)$7.9B